Related Experiment Videos
How far have we reached in tuberculosis vaccine development?
Himanshu Kumar1, Dheeraj Malhotra, Sanjeev Goswami
1National Centre of Applied Human Genetics, School of Life Sciences, Jawaharlal Nehru University, New Delhi-110 067, India.
Critical Reviews in Microbiology
|November 26, 2003
Summary
Tuberculosis remains a leading cause of death globally. This review explores novel vaccine strategies beyond the traditional BCG vaccine to combat Mycobacterium tuberculosis.
Area of Science:
- Infectious diseases
- Immunology
- Bacteriology
Background:
- Tuberculosis (TB) is a major global health threat caused by Mycobacterium tuberculosis.
- Pulmonary TB is the most common and lethal form, with the bacteria evading host immunity.
- Challenges include poor diagnosis, ineffective BCG vaccine, lengthy treatment, and drug-resistant strains, especially in HIV patients.
Purpose of the Study:
- To review current and emerging vaccine strategies for tuberculosis.
- To discuss the potential of novel vaccine platforms and mycobacterial lipids.
- To highlight the need for improved vaccines against Mycobacterium tuberculosis.
Main Methods:
- Literature review of tuberculosis vaccines.
- Discussion of traditional BCG, auxotrophic, subunit, and DNA vaccines.
- Exploration of mycobacterial lipids as vaccines or adjuvants.
Main Results:
- The current BCG vaccine has limited efficacy.
- New vaccine technologies offer potential for improved TB control.
- Mycobacterial lipids show promise as future vaccine components.
Conclusions:
- Advanced bioinformatics and genomic data facilitate the development of new TB vaccines.
- Novel strategies are crucial to replace the traditional BCG vaccine and combat drug-resistant TB.
- Effective short-term chemotherapy and vaccines are urgently needed, particularly for HIV-infected individuals.